Inhaled long-acting β-adrenergic agonists (LABAs) and short-acting β-adrenergic agonists
are approved for the treatment of obstructive lung disease via actions mediated by β 2 …

Introduction Asthma, a heterogeneous disease, is characterized by chronic airway
inflammation and hyperreactivity. β2-adrenoreceptor agonists (β2-agonists) remain pivotal …

ABSTRACT Introduction: The use of LAMAs in asthma is now supported by pharmacological
and clinical evidence, whereas the effectiveness of therapy with ICS/LABA/LAMA fixed dose …

Night-time and early morning symptoms are common and uncomfortable in many patients
with COPD, and likely to negatively influence their long-term outcomes. However, it is still …

G protein‐coupled receptors (GPCRs) are valuable therapeutic targets for many diseases. A
central question of GPCR drug discovery is to understand what determines the agonism or …

β2-Adrenoceptor (β2-AR) agonists are widely used as bronchodilators. The emerge of
ultralong acting β2-agonists is an important breakthrough in pulmonary medicine. In this …

The first chiral methodology enabling the separation of indacaterol enantiomers was
developed in this work by cyclodextrin-electrokinetic chromatography. Indacaterol (IND) is a …

Highlights What are the main findings? FF/Vi is an effective choice for patients who are
uncontrolled on their current Asthma treatment and also for controlled Asthma patients …

Background Indacaterol maleate delivered with the Breezhaler® inhalation device is a long-
acting β 2-agonist approved for chronic obstructive pulmonary disease. In the development …

Agonists of the β2 adrenergic receptor (ADRB2) are an important class of medications used
for the treatment of respiratory diseases. They can be classified as short acting (SABA) or …